Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

Eric Van Cutsem(Universitair Ziekenhuis Leuven), David Cunningham(Royal Marsden NHS Foundation Trust), Vassilis Georgoulias(Hellenic Oncology Research Group), M. Mazier(PAREXEL International (France)), Scott Berry, John Bridgewater(University College London Hospitals NHS Foundation Trust), Fernando Rivera(Marqués de Valdecilla University Hospital), Albrecht Kretzschmar(Roche (Switzerland)), Marc Peeters(University of Antwerp), J.-L. Canon(Queen Fabiola Children's University Hospital), M. Michael(Peter MacCallum Cancer Centre)
Annals of Oncology
May 1, 2009
10.1093/annonc/mdp233
Cited by 534

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k